Identification

Name
Bepridil
Accession Number
DB01244  (APRD00727)
Type
Small Molecule
Groups
Approved, Withdrawn
Description

A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. [PubChem] It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes).

Structure
Thumb
Synonyms
  • Bepadin
  • Bepridil
Product Ingredients
IngredientUNIICASInChI Key
Bepridil hydrochloride4W2P15D93M74764-40-2UEECHQPWQHYEDE-UHFFFAOYSA-N
International/Other Brands
Angopril / Cordium / Vascor
Categories
UNII
755BO701MA
CAS number
64706-54-3
Weight
Average: 366.5396
Monoisotopic: 366.26711372
Chemical Formula
C24H34N2O
InChI Key
UIEATEWHFDRYRU-UHFFFAOYSA-N
InChI
InChI=1S/C24H34N2O/c1-21(2)19-27-20-24(25-15-9-10-16-25)18-26(23-13-7-4-8-14-23)17-22-11-5-3-6-12-22/h3-8,11-14,21,24H,9-10,15-20H2,1-2H3
IUPAC Name
N-benzyl-N-[3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl]aniline
SMILES
CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1

Pharmacology

Indication

For the treatment of hypertension, and chronic stable angina (classic effort-associated angina).

Pharmacodynamics

Bepridil is a calcium channel blocker that has well characterized anti-anginal properties and known but poorly characterized type 1 anti-arrhythmic and anti-hypertensive properties. It is not related chemically to other calcium channel blockers such as diltiazem hydrochloride, nifedipine and verapamil hydrochloride.

Mechanism of action

Bepridil has inhibitory effects on both the slow calcium (L-type) and fast sodium inward currents in myocardial and vascular smooth muscle, interferes with calcium binding to calmodulin, and blocks both voltage and receptor operated calcium channels. Bepridil inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle. This has been demonstrated in isolated myocardial and vascular smooth muscle preparations in which both the slope of the calcium dose response curve and the maximum calcium-induced inotropic response were significantly reduced by bepridil. In cardiac myocytes in vitro, bepridil was shown to be tightly bound to actin. Bepridil regularly reduces heart rate and arterial pressure at rest and at a given level of exercise by dilating peripheral arterioles and reducing total peripheral resistance (afterload) against which the heart works.

TargetActionsOrganism
AVoltage-dependent P/Q-type calcium channel subunit alpha-1A
inhibitor
Human
AVoltage-dependent T-type calcium channel subunit alpha-1H
inhibitor
Human
AVoltage-dependent calcium channel subunit alpha-2/delta-2
inhibitor
Human
USodium/potassium-transporting ATPase subunit alpha-1
inhibitor
Human
UPotassium voltage-gated channel subfamily KQT member 1
inhibitor
Human
UTroponin C, slow skeletal and cardiac muscles
other
Human
UCalmodulin
binder
Human
UCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B
inhibitor
Human
UCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A
inhibitor
Human
UPotassium voltage-gated channel subfamily H member 2
inhibitor
Human
Absorption

Rapidly and completely absorbed after oral administration.

Volume of distribution
Not Available
Protein binding

99%

Metabolism

Hepatic.

Route of elimination
Not Available
Half life

24-50 hours

Clearance
Not Available
Toxicity

There has been one experience with overdosage in which a patient inadvertently took a single dose of 1600 mg of bepridil. The patient was observed for 72 hours in intensive care, but no significant adverse experiences were noted.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbafunginThe therapeutic efficacy of Abafungin can be increased when used in combination with Bepridil.Investigational
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Bepridil.Approved, Investigational
AbexinostatThe risk or severity of QTc prolongation can be increased when Abexinostat is combined with Bepridil.Investigational
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Bepridil.Approved, Investigational
AceclofenacThe therapeutic efficacy of Bepridil can be decreased when used in combination with Aceclofenac.Approved, Investigational
AcemetacinThe therapeutic efficacy of Bepridil can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcepromazineThe risk or severity of hypotension can be increased when Acepromazine is combined with Bepridil.Approved, Vet Approved
AceprometazineThe risk or severity of QTc prolongation can be increased when Aceprometazine is combined with Bepridil.Approved
Acetylsalicylic acidThe therapeutic efficacy of Bepridil can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AcrivastineThe risk or severity of QTc prolongation can be increased when Acrivastine is combined with Bepridil.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Bepridil.Approved
AlbaconazoleThe therapeutic efficacy of Albaconazole can be increased when used in combination with Bepridil.Investigational
AlcaftadineThe risk or severity of QTc prolongation can be increased when Alcaftadine is combined with Bepridil.Approved
AlclofenacThe therapeutic efficacy of Bepridil can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlcuroniumBepridil may increase the neuromuscular blocking activities of Alcuronium.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Bepridil is combined with Aldesleukin.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Bepridil.Experimental, Investigational
AlfuzosinAlfuzosin may increase the hypotensive activities of Bepridil.Approved, Investigational
AlimemazineThe risk or severity of QTc prolongation can be increased when Alimemazine is combined with Bepridil.Approved, Vet Approved
AliskirenBepridil may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Bepridil.Approved, Investigational
AlminoprofenThe therapeutic efficacy of Bepridil can be decreased when used in combination with Alminoprofen.Experimental
AlprenololBepridil may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AmantadineThe risk or severity of QTc prolongation can be increased when Amantadine is combined with Bepridil.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Bepridil.Approved, Investigational
AmifampridineThe risk or severity of QTc prolongation can be increased when Amifampridine is combined with Bepridil.Approved
AmifostineBepridil may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Bepridil is combined with Amiloride.Approved
AminophenazoneThe therapeutic efficacy of Bepridil can be decreased when used in combination with Aminophenazone.Approved, Withdrawn
AmiodaroneThe risk or severity of QTc prolongation can be increased when Amiodarone is combined with Bepridil.Approved, Investigational
AmitriptylineThe risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Bepridil.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Bepridil.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Bepridil.Approved, Illicit
AmodiaquineThe risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Bepridil.Approved, Investigational
AmoxapineThe risk or severity of QTc prolongation can be increased when Amoxapine is combined with Bepridil.Approved
Amphotericin BBepridil may decrease the nephrotoxic activities of Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Amprenavir can be increased when it is combined with Bepridil.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Bepridil is combined with Amyl Nitrite.Approved
AnagrelideThe risk or severity of QTc prolongation can be increased when Anagrelide is combined with Bepridil.Approved
AntazolineThe risk or severity of QTc prolongation can be increased when Antazoline is combined with Bepridil.Approved
AntipyrineThe therapeutic efficacy of Bepridil can be decreased when used in combination with Antipyrine.Approved, Investigational
AntrafenineThe therapeutic efficacy of Bepridil can be decreased when used in combination with Antrafenine.Approved
ApalutamideThe serum concentration of Bepridil can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Bepridil.Approved
ApomorphineThe risk or severity of QTc prolongation can be increased when Apomorphine is combined with Bepridil.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Bepridil is combined with Apraclonidine.Approved
AprepitantThe serum concentration of Bepridil can be increased when it is combined with Aprepitant.Approved, Investigational
ArformoterolThe risk or severity of QTc prolongation can be increased when Arformoterol is combined with Bepridil.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Bepridil.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of QTc prolongation can be increased when Aripiprazole lauroxil is combined with Bepridil.Approved, Investigational
ArotinololThe risk or severity of hypotension can be increased when Arotinolol is combined with Bepridil.Investigational
Arsenic trioxideThe risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Bepridil.Approved, Investigational
ArtemetherThe risk or severity of QTc prolongation can be increased when Artemether is combined with Bepridil.Approved
Ascorbic acidThe serum concentration of Ascorbic acid can be increased when it is combined with Bepridil.Approved, Nutraceutical
AsenapineThe risk or severity of QTc prolongation can be increased when Asenapine is combined with Bepridil.Approved
AstemizoleThe risk or severity of QTc prolongation can be increased when Astemizole is combined with Bepridil.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Bepridil.Approved, Investigational, Withdrawn
AtazanavirThe risk or severity of QTc prolongation can be increased when Atazanavir is combined with Bepridil.Approved, Investigational
AtenololAtenolol may increase the hypotensive activities of Bepridil.Approved
AtomoxetineThe risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Bepridil.Approved
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Bepridil.Approved
AtracuriumBepridil may increase the neuromuscular blocking activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateBepridil may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AvanafilAvanafil may increase the antihypertensive activities of Bepridil.Approved
AvatrombopagThe serum concentration of Avatrombopag can be increased when it is combined with Bepridil.Approved, Investigational
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Bepridil.Approved, Investigational
AzapropazoneThe therapeutic efficacy of Bepridil can be decreased when used in combination with Azapropazone.Withdrawn
AzatadineThe risk or severity of QTc prolongation can be increased when Azatadine is combined with Bepridil.Approved
AzelastineThe risk or severity of QTc prolongation can be increased when Azelastine is combined with Bepridil.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Bepridil is combined with Azilsartan medoxomil.Approved, Investigational
AzithromycinThe risk or severity of QTc prolongation can be increased when Azithromycin is combined with Bepridil.Approved
BalsalazideThe therapeutic efficacy of Bepridil can be decreased when used in combination with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Bepridil.Experimental
BarbitalBarbital may increase the hypotensive activities of Bepridil.Illicit
BaricitinibThe serum concentration of Baricitinib can be increased when it is combined with Bepridil.Approved, Investigational
BarnidipineBepridil may increase the antihypertensive activities of Barnidipine.Approved
BedaquilineThe risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Bepridil.Approved
BelinostatThe serum concentration of Belinostat can be increased when it is combined with Bepridil.Approved, Investigational
BenazeprilBenazepril may increase the hypotensive activities of Bepridil.Approved, Investigational
BenazeprilatBepridil may increase the hypotensive activities of Benazeprilat.Experimental
BendazacThe therapeutic efficacy of Bepridil can be decreased when used in combination with Bendazac.Experimental
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Bepridil.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Bepridil.Withdrawn
BenorilateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Bepridil can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzatropineThe risk or severity of QTc prolongation can be increased when Benzatropine is combined with Bepridil.Approved
BenzydamineThe therapeutic efficacy of Bepridil can be decreased when used in combination with Benzydamine.Approved
BesifloxacinThe risk or severity of QTc prolongation can be increased when Besifloxacin is combined with Bepridil.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Bepridil.Approved, Vet Approved
BetaxololBetaxolol may increase the hypotensive activities of Bepridil.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Bepridil.Approved
BevantololThe risk or severity of hypotension can be increased when Bevantolol is combined with Bepridil.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Bepridil.Experimental
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Bepridil.Approved, Investigational
BilastineThe risk or severity of QTc prolongation can be increased when Bilastine is combined with Bepridil.Approved, Investigational
BimatoprostBimatoprost may increase the hypotensive activities of Bepridil.Approved, Investigational
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Bepridil.Approved
BisoprololBisoprolol may increase the hypotensive activities of Bepridil.Approved
BisoxatinThe therapeutic efficacy of Bisoxatin can be decreased when used in combination with Bepridil.Approved
BoceprevirThe serum concentration of Bepridil can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe risk or severity of QTc prolongation can be increased when Bortezomib is combined with Bepridil.Approved, Investigational
BosentanThe serum concentration of Bepridil can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Bepridil.Approved
BQ-123Bepridil may increase the hypotensive activities of BQ-123.Investigational
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Bepridil.Approved, Investigational
BretyliumBretylium may increase the hypotensive activities of Bepridil.Approved
BrexpiprazoleThe risk or severity of hypotension can be increased when Brexpiprazole is combined with Bepridil.Approved, Investigational
BromfenacThe therapeutic efficacy of Bepridil can be decreased when used in combination with Bromfenac.Approved
BromocriptineThe risk or severity of hypotension can be increased when Bromocriptine is combined with Bepridil.Approved, Investigational
BromperidolThe serum concentration of Bromperidol can be increased when it is combined with Bepridil.Approved, Investigational
BrompheniramineThe risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Bepridil.Approved
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Bepridil.Investigational
BuclizineThe risk or severity of QTc prolongation can be increased when Buclizine is combined with Bepridil.Approved
BufexamacThe therapeutic efficacy of Bepridil can be decreased when used in combination with Bufexamac.Approved, Experimental
BumadizoneThe therapeutic efficacy of Bepridil can be decreased when used in combination with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bepridil is combined with Bumetanide.Approved
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Bepridil.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bepridil is combined with Bupivacaine.Approved, Investigational
BupranololBepridil may increase the hypotensive activities of Bupranolol.Approved
BuserelinThe risk or severity of QTc prolongation can be increased when Buserelin is combined with Bepridil.Approved, Investigational
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Bepridil.Approved
ButriptylineThe risk or severity of QTc prolongation can be increased when Butriptyline is combined with Bepridil.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Bepridil.Approved
CadralazineCadralazine may increase the hypotensive activities of Bepridil.Experimental
Calcium AcetateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium Phosphate.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Bepridil.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Bepridil.Approved
CandesartanBepridil may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Bepridil.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Bepridil.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Bepridil.Approved
CarbamazepineThe metabolism of Bepridil can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe therapeutic efficacy of Bepridil can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Bepridil is combined with Carbetocin.Approved, Investigational
CarbinoxamineThe risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Bepridil.Approved
CarboxymethylcelluloseThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Bepridil.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Bepridil.Approved, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Bepridil.Withdrawn
CarprofenThe therapeutic efficacy of Bepridil can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololBepridil may increase the hypotensive activities of Carteolol.Approved
CarvedilolThe risk or severity of hypotension can be increased when Carvedilol is combined with Bepridil.Approved, Investigational
Castor oilThe therapeutic efficacy of Castor oil can be decreased when used in combination with Bepridil.Approved, Investigational, Nutraceutical, Vet Approved
CelecoxibThe therapeutic efficacy of Bepridil can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Bepridil.Approved, Investigational
CeritinibThe serum concentration of Bepridil can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Bepridil.Approved, Withdrawn
Cerliponase alfaThe serum concentration of Cerliponase alfa can be increased when it is combined with Bepridil.Approved, Investigational
CetirizineThe risk or severity of QTc prolongation can be increased when Cetirizine is combined with Bepridil.Approved
ChlorambucilThe serum concentration of Chlorambucil can be increased when it is combined with Bepridil.Approved
ChlorcyclizineThe risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Bepridil.Approved
ChloroquineThe risk or severity of QTc prolongation can be increased when Chloroquine is combined with Bepridil.Approved, Investigational, Vet Approved
ChlorothiazideChlorothiazide may increase the hypotensive activities of Bepridil.Approved, Vet Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Chlorphenamine is combined with Bepridil.Approved
ChlorpromazineThe risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Bepridil.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Bepridil.Approved, Investigational, Withdrawn
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Bepridil.Approved
Choline magnesium trisalicylateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CicletanineBepridil may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilBepridil may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Bepridil is combined with Cilnidipine.Approved, Investigational
CilostazolThe risk or severity of QTc prolongation can be increased when Cilostazol is combined with Bepridil.Approved, Investigational
CimetidineThe serum concentration of Bepridil can be increased when it is combined with Cimetidine.Approved, Investigational
CimicoxibThe therapeutic efficacy of Bepridil can be decreased when used in combination with Cimicoxib.Investigational
CinnarizineThe risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Bepridil.Approved, Investigational
CinoxacinThe risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Bepridil.Approved, Investigational, Withdrawn
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Bepridil.Approved, Investigational
CisaprideCisapride may increase the QTc-prolonging activities of Bepridil.Approved, Investigational, Withdrawn
CisatracuriumBepridil may increase the neuromuscular blocking activities of Cisatracurium.Approved
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Bepridil.Approved
CitalopramThe risk or severity of QTc prolongation can be increased when Citalopram is combined with Bepridil.Approved
ClarithromycinThe risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Bepridil.Approved
ClemastineThe risk or severity of QTc prolongation can be increased when Bepridil is combined with Clemastine.Approved, Investigational
ClevidipineThe risk or severity of adverse effects can be increased when Bepridil is combined with Clevidipine.Approved, Investigational
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Bepridil.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Bepridil is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of QTc prolongation can be increased when Clomipramine is combined with Bepridil.Approved, Investigational, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Bepridil.Approved
ClonixinThe therapeutic efficacy of Bepridil can be decreased when used in combination with Clonixin.Approved
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Bepridil.Approved
CloranololBepridil may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Bepridil can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of QTc prolongation can be increased when Clozapine is combined with Bepridil.Approved
CobicistatThe metabolism of Bepridil can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Bepridil.Approved, Investigational
CocaineThe risk or severity of QTc prolongation can be increased when Bepridil is combined with Cocaine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Bepridil.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Bepridil.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated estrogens can be increased when it is combined with Bepridil.Approved
CopanlisibThe serum concentration of Copanlisib can be increased when it is combined with Bepridil.Approved, Investigational
CrizotinibThe risk or severity of QTc prolongation can be increased when Crizotinib is combined with Bepridil.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Bepridil.Approved
CUDC-101The risk or severity of QTc prolongation can be increased when CUDC-101 is combined with Bepridil.Investigational
CUDC-907The risk or severity of QTc prolongation can be increased when CUDC-907 is combined with Bepridil.Investigational
CurcuminThe metabolism of Bepridil can be decreased when combined with Curcumin.Approved, Investigational
CyclizineThe risk or severity of QTc prolongation can be increased when Cyclizine is combined with Bepridil.Approved
CyclopenthiazideBepridil may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Bepridil.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Bepridil.Approved
CyproheptadineThe risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Bepridil.Approved
CytarabineThe serum concentration of Cytarabine can be increased when it is combined with Bepridil.Approved, Investigational
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Bepridil.Approved
DabrafenibThe serum concentration of Bepridil can be decreased when it is combined with Dabrafenib.Approved, Investigational
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Bepridil.Approved, Investigational
DanazolThe metabolism of Bepridil can be decreased when combined with Danazol.Approved
DanthronThe therapeutic efficacy of Danthron can be decreased when used in combination with Bepridil.Approved, Investigational, Withdrawn
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Bepridil.Approved
DapiprazoleThe risk or severity of hypotension can be increased when Dapiprazole is combined with Bepridil.Approved
DarunavirThe metabolism of Bepridil can be decreased when combined with Darunavir.Approved
DasabuvirThe serum concentration of Dasabuvir can be increased when it is combined with Bepridil.Approved
DasatinibThe serum concentration of Bepridil can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Bepridil.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Bepridil.Approved, Investigational
DeferasiroxThe serum concentration of Bepridil can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixThe risk or severity of QTc prolongation can be increased when Degarelix is combined with Bepridil.Approved
DelamanidThe risk or severity of QTc prolongation can be increased when Delamanid is combined with Bepridil.Approved, Investigational
DelaprilBepridil may increase the hypotensive activities of Delapril.Investigational
DelavirdineThe metabolism of Bepridil can be decreased when combined with Delavirdine.Approved
DeserpidineBepridil may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of QTc prolongation can be increased when Desflurane is combined with Bepridil.Approved
DesipramineThe risk or severity of QTc prolongation can be increased when Desipramine is combined with Bepridil.Approved, Investigational
DesloratadineThe risk or severity of QTc prolongation can be increased when Desloratadine is combined with Bepridil.Approved, Investigational
DeutetrabenazineThe risk or severity of QTc prolongation can be increased when Bepridil is combined with Deutetrabenazine.Approved, Investigational
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Bepridil.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Bepridil.Approved
DexchlorpheniramineThe risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Bepridil.Experimental, Investigational
Dexchlorpheniramine maleateThe risk or severity of QTc prolongation can be increased when Dexchlorpheniramine maleate is combined with Bepridil.Approved
DexibuprofenThe therapeutic efficacy of Bepridil can be decreased when used in combination with Dexibuprofen.Approved, Investigational
DexketoprofenThe therapeutic efficacy of Bepridil can be decreased when used in combination with Dexketoprofen.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Bepridil is combined with Dexmedetomidine.Approved, Vet Approved
DexniguldipineBepridil may increase the hypotensive activities of Dexniguldipine.Experimental
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Bepridil.Approved, Illicit, Investigational, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Bepridil.Approved
DiclofenacThe therapeutic efficacy of Bepridil can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Bepridil is combined with Diclofenamide.Approved, Investigational
DiethylnorspermineBepridil may increase the hypotensive activities of Diethylnorspermine.Investigational
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Bepridil.Approved, Investigational
DifenpiramideThe therapeutic efficacy of Bepridil can be decreased when used in combination with Difenpiramide.Experimental
DifloxacinThe risk or severity of QTc prolongation can be increased when Difloxacin is combined with Bepridil.Vet Approved
DiflunisalThe therapeutic efficacy of Bepridil can be decreased when used in combination with Diflunisal.Approved, Investigational
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Bepridil.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Bepridil.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Bepridil.Approved, Investigational
DihydroergotamineThe risk or severity of hypotension can be increased when Dihydroergotamine is combined with Bepridil.Approved, Investigational
DiltiazemThe metabolism of Bepridil can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Bepridil.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Bepridil is combined with Dinutuximab.Approved, Investigational
DiphenhydramineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Bepridil.Approved, Investigational
DipyridamoleDipyridamole may increase the antihypertensive activities of Bepridil.Approved
DisopyramideThe risk or severity of QTc prolongation can be increased when Disopyramide is combined with Bepridil.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Bepridil.Approved, Investigational
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Bepridil.Approved
DofetilideThe risk or severity of QTc prolongation can be increased when Dofetilide is combined with Bepridil.Approved, Investigational
DolasetronThe risk or severity of QTc prolongation can be increased when Dolasetron is combined with Bepridil.Approved, Investigational
DolutegravirThe serum concentration of Dolutegravir can be increased when it is combined with Bepridil.Approved
DomperidoneThe risk or severity of QTc prolongation can be increased when Domperidone is combined with Bepridil.Approved, Investigational, Vet Approved
DonepezilThe risk or severity of QTc prolongation can be increased when Donepezil is combined with Bepridil.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Bepridil.Approved
DosulepinThe risk or severity of QTc prolongation can be increased when Dosulepin is combined with Bepridil.Approved
DoxacuriumBepridil may increase the neuromuscular blocking activities of Doxacurium.Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Bepridil.Approved
DoxepinThe risk or severity of QTc prolongation can be increased when Doxepin is combined with Bepridil.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Bepridil.Approved, Investigational
DoxycyclineThe metabolism of Bepridil can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineThe risk or severity of QTc prolongation can be increased when Doxylamine is combined with Bepridil.Approved, Vet Approved
DronedaroneThe risk or severity of QTc prolongation can be increased when Dronedarone is combined with Bepridil.Approved
DroperidolThe risk or severity of QTc prolongation can be increased when Droperidol is combined with Bepridil.Approved, Vet Approved
DroxicamThe therapeutic efficacy of Bepridil can be decreased when used in combination with Droxicam.Withdrawn
DuloxetineBepridil may increase the orthostatic hypotensive activities of Duloxetine.Approved
EbastineThe risk or severity of QTc prolongation can be increased when Ebastine is combined with Bepridil.Approved, Investigational
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Bepridil.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Bepridil.Approved
EfavirenzThe risk or severity of ventricular arrhythmias can be increased when Efavirenz is combined with Bepridil.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Bepridil.Approved
EfonidipineBepridil may increase the hypotensive activities of Efonidipine.Approved, Investigational
ElagolixThe serum concentration of Elagolix can be increased when it is combined with Bepridil.Approved, Investigational
ElbasvirThe serum concentration of Elbasvir can be increased when it is combined with Bepridil.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Bepridil.Approved, Investigational
EliglustatThe risk or severity of QTc prolongation can be increased when Eliglustat is combined with Bepridil.Approved
EmedastineThe risk or severity of QTc prolongation can be increased when Emedastine is combined with Bepridil.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Bepridil is combined with Empagliflozin.Approved
EnalaprilEnalapril may increase the hypotensive activities of Bepridil.Approved, Vet Approved
EnalaprilatBepridil may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Bepridil.Experimental
EnoxacinThe risk or severity of QTc prolongation can be increased when Enoxacin is combined with Bepridil.Approved, Investigational
EntinostatThe risk or severity of QTc prolongation can be increased when Entinostat is combined with Bepridil.Investigational
EnzalutamideThe serum concentration of Bepridil can be decreased when it is combined with Enzalutamide.Approved
EpanololBepridil may increase the hypotensive activities of Epanolol.Experimental
EpinastineThe risk or severity of QTc prolongation can be increased when Epinastine is combined with Bepridil.Approved, Investigational
EpirizoleThe therapeutic efficacy of Bepridil can be decreased when used in combination with Epirizole.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Bepridil is combined with Eplerenone.Approved
EpoprostenolEpoprostenol may increase the hypotensive activities of Bepridil.Approved
EprosartanEprosartan may increase the hypotensive activities of Bepridil.Approved
ErgotamineThe risk or severity of hypotension can be increased when Ergotamine is combined with Bepridil.Approved
EribulinThe risk or severity of QTc prolongation can be increased when Eribulin is combined with Bepridil.Approved, Investigational
ErlotinibThe risk or severity of QTc prolongation can be increased when Bepridil is combined with Erlotinib.Approved, Investigational
ErtugliflozinThe serum concentration of Ertugliflozin can be increased when it is combined with Bepridil.Approved, Investigational
ErythromycinThe risk or severity of QTc prolongation can be increased when Erythromycin is combined with Bepridil.Approved, Investigational, Vet Approved
EsatenololBepridil may increase the hypotensive activities of Esatenolol.Experimental
EscitalopramThe risk or severity of QTc prolongation can be increased when Escitalopram is combined with Bepridil.Approved, Investigational
EsmololBepridil may increase the hypotensive activities of Esmolol.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Bepridil.Approved, Investigational, Vet Approved
Estradiol acetateThe serum concentration of Estradiol acetate can be increased when it is combined with Bepridil.Approved, Investigational, Vet Approved
Estradiol benzoateThe serum concentration of Estradiol benzoate can be increased when it is combined with Bepridil.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be increased when it is combined with Bepridil.Approved, Investigational, Vet Approved
Estradiol dienanthateThe serum concentration of Estradiol dienanthate can be increased when it is combined with Bepridil.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be increased when it is combined with Bepridil.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Bepridil.Approved, Investigational, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Bepridil.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Bepridil is combined with Etacrynic acid.Approved, Investigational
EthenzamideThe therapeutic efficacy of Bepridil can be decreased when used in combination with Ethenzamide.Experimental
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Bepridil.Approved
EtodolacThe therapeutic efficacy of Bepridil can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Etofenamate.Approved, Investigational
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Bepridil.Approved
EtoricoxibThe therapeutic efficacy of Bepridil can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Bepridil can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Bepridil.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Bepridil.Approved
EzogabineThe risk or severity of QTc prolongation can be increased when Ezogabine is combined with Bepridil.Approved, Investigational
FamotidineThe risk or severity of QTc prolongation can be increased when Famotidine is combined with Bepridil.Approved
FelbamateThe risk or severity of QTc prolongation can be increased when Felbamate is combined with Bepridil.Approved
FelbinacThe therapeutic efficacy of Bepridil can be decreased when used in combination with Felbinac.Experimental
FelodipineFelodipine may increase the hypotensive activities of Bepridil.Approved, Investigational
FenbufenThe therapeutic efficacy of Bepridil can be decreased when used in combination with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Bepridil.Approved
FenoprofenThe therapeutic efficacy of Bepridil can be decreased when used in combination with Fenoprofen.Approved
FentiazacThe therapeutic efficacy of Bepridil can be decreased when used in combination with Fentiazac.Experimental
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Bepridil.Experimental
FeprazoneThe therapeutic efficacy of Bepridil can be decreased when used in combination with Feprazone.Experimental
Ferulic acidBepridil may increase the hypotensive activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Bepridil.Approved
FexofenadineThe risk or severity of QTc prolongation can be increased when Fexofenadine is combined with Bepridil.Approved, Investigational
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Bepridil.Approved
FimasartanThe risk or severity of adverse effects can be increased when Bepridil is combined with Fimasartan.Approved, Investigational
FingolimodThe risk or severity of QTc prolongation can be increased when Fingolimod is combined with Bepridil.Approved, Investigational
FirocoxibThe therapeutic efficacy of Bepridil can be decreased when used in combination with Firocoxib.Experimental, Vet Approved
FlecainideThe risk or severity of QTc prolongation can be increased when Flecainide is combined with Bepridil.Approved, Withdrawn
FleroxacinThe risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Bepridil.Approved
FloctafenineThe therapeutic efficacy of Bepridil can be decreased when used in combination with Floctafenine.Approved, Withdrawn
Fluciclovine (18F)The serum concentration of Fluciclovine (18F) can be increased when it is combined with Bepridil.Approved
FluconazoleThe risk or severity of QTc prolongation can be increased when Fluconazole is combined with Bepridil.Approved, Investigational
FlumequineThe risk or severity of QTc prolongation can be increased when Flumequine is combined with Bepridil.Withdrawn
FlunixinThe therapeutic efficacy of Bepridil can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Bepridil can be decreased when used in combination with Flunoxaprofen.Experimental
FluorouracilThe risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Bepridil.Approved
FluoxetineThe risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Bepridil.Approved, Vet Approved
FlupentixolThe risk or severity of QTc prolongation can be increased when Flupentixol is combined with Bepridil.Approved, Investigational, Withdrawn
FlurbiprofenThe therapeutic efficacy of Bepridil can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FluticasoneThe serum concentration of Fluticasone can be increased when it is combined with Bepridil.Approved, Experimental, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Bepridil.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Bepridil.Approved
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Bepridil.Experimental
FluvoxamineThe metabolism of Bepridil can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe risk or severity of QTc prolongation can be increased when Formoterol is combined with Bepridil.Approved, Investigational
FosamprenavirThe metabolism of Bepridil can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Bepridil can be increased when it is combined with Fosaprepitant.Approved
FoscarnetThe risk or severity of QTc prolongation can be increased when Foscarnet is combined with Bepridil.Approved
FosinoprilFosinopril may increase the hypotensive activities of Bepridil.Approved
FosinoprilatBepridil may increase the hypotensive activities of Fosinoprilat.Experimental
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Bepridil.Approved, Investigational
FostamatinibFostamatinib may increase the antihypertensive activities of Bepridil.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Bepridil.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Bepridil is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Bepridil can be increased when it is combined with Fusidic Acid.Approved, Investigational
Gadobenic acidThe risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Bepridil.Approved, Investigational
GalantamineThe risk or severity of QTc prolongation can be increased when Galantamine is combined with Bepridil.Approved
GallamineBepridil may increase the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideBepridil may increase the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GarenoxacinThe risk or severity of QTc prolongation can be increased when Garenoxacin is combined with Bepridil.Investigational
GatifloxacinThe risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Bepridil.Approved, Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Bepridil.Approved, Investigational
GemifloxacinThe risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Bepridil.Approved, Investigational
GivinostatThe risk or severity of QTc prolongation can be increased when Givinostat is combined with Bepridil.Investigational
GlecaprevirThe serum concentration of Glecaprevir can be increased when it is combined with Bepridil.Approved, Investigational
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Bepridil.Approved, Investigational
GoserelinThe risk or severity of QTc prolongation can be increased when Goserelin is combined with Bepridil.Approved
Gramicidin DThe serum concentration of Gramicidin D can be increased when it is combined with Bepridil.Approved
GranisetronThe risk or severity of QTc prolongation can be increased when Granisetron is combined with Bepridil.Approved, Investigational
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Bepridil.Approved
GrepafloxacinThe risk or severity of QTc prolongation can be increased when Grepafloxacin is combined with Bepridil.Approved, Investigational, Withdrawn
GuacetisalThe therapeutic efficacy of Bepridil can be decreased when used in combination with Guacetisal.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Bepridil.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Bepridil.Approved
GuanazodineBepridil may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Bepridil.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Bepridil.Approved, Investigational
GuanoclorBepridil may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzBepridil may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanBepridil may increase the hypotensive activities of Guanoxan.Experimental
HalofantrineThe risk or severity of QTc prolongation can be increased when Bepridil is combined with Halofantrine.Approved
HaloperidolThe risk or severity of QTc prolongation can be increased when Haloperidol is combined with Bepridil.Approved
HalothaneThe risk or severity of adverse effects can be increased when Bepridil is combined with Halothane.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Bepridil.Experimental
HexamethoniumBepridil may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Bepridil.Approved
HistrelinThe risk or severity of QTc prolongation can be increased when Histrelin is combined with Bepridil.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Bepridil.Experimental
HydralazineHydralazine may increase the hypotensive activities of Bepridil.Approved
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Bepridil.Approved, Vet Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Bepridil.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Bepridil.Approved, Investigational
HydroxychloroquineThe risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Bepridil.Approved
HydroxyureaThe serum concentration of Hydroxyurea can be increased when it is combined with Bepridil.Approved
HydroxyzineThe risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Bepridil.Approved
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Bepridil.Approved, Investigational
IbuprofenThe therapeutic efficacy of Bepridil can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Bepridil can be decreased when used in combination with Ibuproxam.Withdrawn
IbutilideThe risk or severity of QTc prolongation can be increased when Ibutilide is combined with Bepridil.Approved
IcosapentThe therapeutic efficacy of Bepridil can be decreased when used in combination with Icosapent.Approved, Nutraceutical
IdelalisibThe metabolism of Bepridil can be decreased when combined with Idelalisib.Approved
IloperidoneThe risk or severity of QTc prolongation can be increased when Iloperidone is combined with Bepridil.Approved
IloprostIloprost may increase the hypotensive activities of Bepridil.Approved, Investigational
ImatinibThe risk or severity of QTc prolongation can be increased when Bepridil is combined with Imatinib.Approved
ImidaprilBepridil may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Imidazole salicylate.Experimental
ImipramineThe risk or severity of QTc prolongation can be increased when Imipramine is combined with Bepridil.Approved
IndacaterolThe risk or severity of QTc prolongation can be increased when Indacaterol is combined with Bepridil.Approved
IndapamideThe risk or severity of QTc prolongation can be increased when Indapamide is combined with Bepridil.Approved
IndenololBepridil may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Bepridil can be decreased when combined with Indinavir.Approved
IndobufenThe therapeutic efficacy of Bepridil can be decreased when used in combination with Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Bepridil can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Bepridil can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Bepridil.Withdrawn
Inotuzumab ozogamicinThe serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Bepridil.Approved, Investigational
IproniazidIproniazid may increase the hypotensive activities of Bepridil.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Bepridil.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Bepridil.Approved, Investigational
IsavuconazoleThe serum concentration of Bepridil can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Bepridil can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Bepridil.Approved
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Bepridil.Approved
IsofluraneThe risk or severity of QTc prolongation can be increased when Isoflurane is combined with Bepridil.Approved, Vet Approved
IsoniazidThe metabolism of Bepridil can be decreased when combined with Isoniazid.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Bepridil is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Bepridil is combined with Isosorbide Mononitrate.Approved
IsoxicamThe therapeutic efficacy of Bepridil can be decreased when used in combination with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Bepridil is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of QTc prolongation can be increased when Isradipine is combined with Bepridil.Approved, Investigational
ItraconazoleThe risk or severity of QTc prolongation can be increased when Itraconazole is combined with Bepridil.Approved, Investigational
IvabradineThe risk or severity of QTc prolongation can be increased when Bepridil is combined with Ivabradine.Approved
IvacaftorThe serum concentration of Bepridil can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Bepridil.Approved, Investigational, Vet Approved
IvosidenibThe risk or severity of QTc prolongation can be increased when Ivosidenib is combined with Bepridil.Approved, Investigational
KebuzoneThe therapeutic efficacy of Bepridil can be decreased when used in combination with Kebuzone.Experimental
KetanserinKetanserin may increase the hypotensive activities of Bepridil.Investigational
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Bepridil.Approved
KetoconazoleThe risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Bepridil.Approved, Investigational
KetoprofenThe therapeutic efficacy of Bepridil can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Bepridil can be decreased when used in combination with Ketorolac.Approved
KetotifenThe risk or severity of QTc prolongation can be increased when Ketotifen is combined with Bepridil.Approved
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Bepridil.Approved
LacidipineBepridil may increase the hypotensive activities of Lacidipine.Approved, Investigational
LactitolThe therapeutic efficacy of Lactitol can be decreased when used in combination with Bepridil.Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Bepridil.Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Bepridil.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Bepridil.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Bepridil.Approved, Investigational
LapatinibThe risk or severity of QTc prolongation can be increased when Lapatinib is combined with Bepridil.Approved, Investigational
LatanoprostLatanoprost may increase the hypotensive activities of Bepridil.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Bepridil.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Bepridil.Approved
LenvatinibThe risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Bepridil.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Bepridil.Approved, Investigational
LetermovirThe serum concentration of Letermovir can be increased when it is combined with Bepridil.Approved, Investigational
LeuprolideThe risk or severity of QTc prolongation can be increased when Leuprolide is combined with Bepridil.Approved, Investigational
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Bepridil.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Bepridil is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Bepridil is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of QTc prolongation can be increased when Levocabastine is combined with Bepridil.Approved, Investigational
LevocetirizineThe risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Bepridil.Approved
LevodopaBepridil may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinThe risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Bepridil.Approved, Investigational
Levomethadyl AcetateThe risk or severity of QTc prolongation can be increased when Levomethadyl Acetate is combined with Bepridil.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Bepridil.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Bepridil is combined with Levosimendan.Approved, Investigational
LinaclotideThe therapeutic efficacy of Linaclotide can be decreased when used in combination with Bepridil.Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Bepridil.Approved
LinezolidLinezolid may increase the hypotensive activities of Bepridil.Approved, Investigational
LinsidomineBepridil may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Bepridil.Approved, Investigational
Lithium cationThe risk or severity of QTc prolongation can be increased when Lithium cation is combined with Bepridil.Experimental
LofexidineBepridil may increase the hypotensive activities of Lofexidine.Approved, Investigational
LomefloxacinThe risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Bepridil.Approved, Investigational
LonazolacThe therapeutic efficacy of Bepridil can be decreased when used in combination with Lonazolac.Experimental
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Bepridil.Approved
LopinavirThe risk or severity of QTc prolongation can be increased when Lopinavir is combined with Bepridil.Approved
LoratadineThe risk or severity of QTc prolongation can be increased when Loratadine is combined with Bepridil.Approved, Investigational
LornoxicamThe therapeutic efficacy of Bepridil can be decreased when used in combination with Lornoxicam.Approved, Investigational
LorpiprazoleThe serum concentration of Bepridil can be increased when it is combined with Lorpiprazole.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Bepridil.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Bepridil.Approved, Investigational
LoxoprofenThe therapeutic efficacy of Bepridil can be decreased when used in combination with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Bepridil.Approved, Investigational
LuliconazoleThe serum concentration of Bepridil can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Bepridil can be increased when combined with Lumacaftor.Approved
LumefantrineThe risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Bepridil.Approved
LumiracoxibThe therapeutic efficacy of Bepridil can be decreased when used in combination with Lumiracoxib.Approved, Investigational
LusutrombopagThe serum concentration of Lusutrombopag can be increased when it is combined with Bepridil.Approved, Investigational
MacimorelinThe risk or severity of QTc prolongation can be increased when Bepridil is combined with Macimorelin.Approved, Investigational
MacitentanBepridil may increase the hypotensive activities of Macitentan.Approved
Magnesium carbonateThe therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Bepridil.Approved, Investigational
Magnesium citrateThe therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Bepridil.Approved
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Bepridil is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Bepridil is combined with Magnesium oxide.Approved
Magnesium peroxideThe therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Bepridil.Experimental
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Bepridil is combined with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of hypotension and neuromuscular blockade can be increased when Bepridil is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
ManidipineBepridil may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe therapeutic efficacy of Mannitol can be decreased when used in combination with Bepridil.Approved, Investigational
MaprotilineThe risk or severity of QTc prolongation can be increased when Maprotiline is combined with Bepridil.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Bepridil.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Bepridil.Approved, Investigational
Meclofenamic acidThe therapeutic efficacy of Bepridil can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe therapeutic efficacy of Bepridil can be decreased when used in combination with Mefenamic acid.Approved
MefloquineThe risk or severity of QTc prolongation can be increased when Mefloquine is combined with Bepridil.Approved, Investigational
MeloxicamThe therapeutic efficacy of Bepridil can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MelphalanThe serum concentration of Melphalan can be increased when it is combined with Bepridil.Approved
MepyramineThe risk or severity of QTc prolongation can be increased when Mepyramine is combined with Bepridil.Approved, Vet Approved
MequitazineThe risk or severity of QTc prolongation can be increased when Mequitazine is combined with Bepridil.Approved
MesalazineThe therapeutic efficacy of Bepridil can be decreased when used in combination with Mesalazine.Approved
MesoridazineThe risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Bepridil.Approved, Investigational
MetamizoleThe therapeutic efficacy of Bepridil can be decreased when used in combination with Metamizole.Approved, Investigational, Withdrawn
MethadoneThe risk or severity of QTc prolongation can be increased when Methadone is combined with Bepridil.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Bepridil is combined with Methazolamide.Approved
MethohexitalMethohexital may increase the hypotensive activities of Bepridil.Approved
MethoserpidineBepridil may increase the hypotensive activities of Methoserpidine.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Bepridil.Approved
MethotrimeprazineThe risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Bepridil.Approved, Investigational
MethyclothiazideThe risk or severity of adverse effects can be increased when Bepridil is combined with Methyclothiazide.Approved
Methyl celluloseThe therapeutic efficacy of Methyl cellulose can be decreased when used in combination with Bepridil.Approved
MethyldopaMethyldopa may increase the hypotensive activities of Bepridil.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Bepridil.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Bepridil.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Bepridil.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Bepridil.Approved, Vet Approved
MetipranololMetipranolol may increase the hypotensive activities of Bepridil.Approved
MetoclopramideThe risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Bepridil.Approved, Investigational
MetocurineBepridil may increase the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideBepridil may increase the neuromuscular blocking activities of Metocurine Iodide.Approved, Withdrawn
MetolazoneMetolazone may increase the hypotensive activities of Bepridil.Approved
MetoprololMetoprolol may increase the hypotensive activities of Bepridil.Approved, Investigational
MetronidazoleThe risk or severity of QTc prolongation can be increased when Metronidazole is combined with Bepridil.Approved
MetyrosineBepridil may increase the hypotensive activities of Metyrosine.Approved
MibefradilThe metabolism of Bepridil can be decreased when combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe metabolism of Bepridil can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MifepristoneThe serum concentration of Bepridil can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineMinaprine may increase the hypotensive activities of Bepridil.Approved
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Bepridil.Approved, Vet Approved
MinoxidilMinoxidil may increase the hypotensive activities of Bepridil.Approved, Investigational
MirabegronThe risk or severity of QTc prolongation can be increased when Mirabegron is combined with Bepridil.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Bepridil.Investigational
MirtazapineThe risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Bepridil.Approved
MitomycinThe serum concentration of Mitomycin can be increased when it is combined with Bepridil.Approved
MitotaneThe serum concentration of Bepridil can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Bepridil.Approved, Investigational
MivacuriumBepridil may increase the neuromuscular blocking activities of Mivacurium.Approved
MocetinostatThe risk or severity of QTc prolongation can be increased when Mocetinostat is combined with Bepridil.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Bepridil.Approved, Investigational
ModafinilThe serum concentration of Bepridil can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of QTc prolongation can be increased when Moexipril is combined with Bepridil.Approved
MofebutazoneThe therapeutic efficacy of Bepridil can be decreased when used in combination with Mofebutazone.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Bepridil.Approved, Investigational
MorniflumateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Morniflumate.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Bepridil.Approved, Investigational
MoxidectinThe serum concentration of Moxidectin can be increased when it is combined with Bepridil.Approved, Investigational, Vet Approved
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Bepridil.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Bepridil.Approved, Investigational
MuzolimineBepridil may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Bepridil.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Bepridil is combined with Nabilone.Approved, Investigational
NabumetoneThe therapeutic efficacy of Bepridil can be decreased when used in combination with Nabumetone.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Bepridil.Approved
NafcillinThe therapeutic efficacy of Bepridil can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftopidilBepridil may increase the hypotensive activities of Naftopidil.Investigational
Nalidixic AcidThe risk or severity of QTc prolongation can be increased when Nalidixic Acid is combined with Bepridil.Approved, Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Bepridil.Approved
NaloxoneThe metabolism of Bepridil can be decreased when combined with Naloxone.Approved, Vet Approved
NaproxenThe therapeutic efficacy of Bepridil can be decreased when used in combination with Naproxen.Approved, Vet Approved
NebivololBepridil may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodoneThe risk or severity of hypotension can be increased when Nefazodone is combined with Bepridil.Approved, Withdrawn
NelfinavirThe risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Bepridil.Approved
NemonoxacinThe risk or severity of QTc prolongation can be increased when Nemonoxacin is combined with Bepridil.Investigational
NeostigmineThe serum concentration of Neostigmine can be increased when it is combined with Bepridil.Approved, Vet Approved
NepafenacThe therapeutic efficacy of Bepridil can be decreased when used in combination with Nepafenac.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Bepridil is combined with Nesiritide.Approved, Investigational
NetupitantThe serum concentration of Bepridil can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Bepridil can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the hypotensive activities of Bepridil.Withdrawn
NicardipineThe risk or severity of QTc prolongation can be increased when Nicardipine is combined with Bepridil.Approved, Investigational
NicergolineThe risk or severity of hypotension can be increased when Nicergoline is combined with Bepridil.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Bepridil.Approved, Investigational
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Bepridil.Approved
NifenazoneThe therapeutic efficacy of Bepridil can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Bepridil can be decreased when used in combination with Niflumic Acid.Approved
NiguldipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Bepridil.Experimental
NilotinibThe risk or severity of QTc prolongation can be increased when Nilotinib is combined with Bepridil.Approved, Investigational
NilvadipineBepridil may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideThe therapeutic efficacy of Bepridil can be decreased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Bepridil.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Bepridil.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Bepridil.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Bepridil.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Bepridil is combined with Nitric Oxide.Approved
NitroaspirinThe therapeutic efficacy of Bepridil can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Bepridil is combined with Nitroglycerin.Approved, Investigational
NitroprussideBepridil may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Bepridil is combined with Nitrous acid.Approved, Investigational
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Bepridil.Approved
NorfloxacinThe risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Bepridil.Approved
NortriptylineThe risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Bepridil.Approved
NS-398The therapeutic efficacy of Bepridil can be decreased when used in combination with NS-398.Experimental
ObinutuzumabBepridil may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Bepridil.Withdrawn
OctreotideThe risk or severity of QTc prolongation can be increased when Octreotide is combined with Bepridil.Approved, Investigational
OdanacatibThe serum concentration of Odanacatib can be increased when it is combined with Bepridil.Investigational
OfloxacinThe risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Bepridil.Approved
OlanzapineThe risk or severity of QTc prolongation can be increased when Olanzapine is combined with Bepridil.Approved, Investigational
OlaparibThe metabolism of Bepridil can be decreased when combined with Olaparib.Approved
OlmesartanOlmesartan may increase the hypotensive activities of Bepridil.Approved, Investigational
OlodaterolThe risk or severity of QTc prolongation can be increased when Olodaterol is combined with Bepridil.Approved
OlopatadineThe risk or severity of QTc prolongation can be increased when Olopatadine is combined with Bepridil.Approved
OlsalazineThe therapeutic efficacy of Bepridil can be decreased when used in combination with Olsalazine.Approved
OmapatrilatOmapatrilat may increase the hypotensive activities of Bepridil.Investigational
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Bepridil.Approved, Investigational
OmeprazoleThe serum concentration of Omeprazole can be increased when it is combined with Bepridil.Approved, Investigational, Vet Approved
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Bepridil.Experimental
OndansetronThe risk or severity of QTc prolongation can be increased when Ondansetron is combined with Bepridil.Approved
OrbifloxacinThe risk or severity of QTc prolongation can be increased when Orbifloxacin is combined with Bepridil.Vet Approved
OrphenadrineThe risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Bepridil.Approved
OxaliplatinThe risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Bepridil.Approved, Investigational
OxaprozinThe therapeutic efficacy of Bepridil can be decreased when used in combination with Oxaprozin.Approved
OxatomideThe risk or severity of QTc prolongation can be increased when Oxatomide is combined with Bepridil.Investigational
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Bepridil.Approved
Oxolinic acidThe risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Bepridil.Experimental
OxprenololBepridil may increase the hypotensive activities of Oxprenolol.Approved
OxyphenbutazoneThe therapeutic efficacy of Bepridil can be decreased when used in combination with Oxyphenbutazone.Approved, Withdrawn
OxyphenisatinThe therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Bepridil.Investigational, Withdrawn
OxytocinThe risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bepridil.Approved, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Bepridil.Approved, Vet Approved
PalbociclibThe serum concentration of Bepridil can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of QTc prolongation can be increased when Paliperidone is combined with Bepridil.Approved
PancuroniumBepridil may increase the neuromuscular blocking activities of Pancuronium.Approved
PanobinostatThe risk or severity of QTc prolongation can be increased when Panobinostat is combined with Bepridil.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be increased when it is combined with Bepridil.Approved
PapaverineThe risk or severity of QTc prolongation can be increased when Papaverine is combined with Bepridil.Approved, Investigational
ParecoxibThe therapeutic efficacy of Bepridil can be decreased when used in combination with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Bepridil.Approved
ParitaprevirThe serum concentration of Paritaprevir can be increased when it is combined with Bepridil.Approved, Investigational
ParoxetineThe risk or severity of QTc prolongation can be increased when Paroxetine is combined with Bepridil.Approved, Investigational
PasireotideThe risk or severity of QTc prolongation can be increased when Pasireotide is combined with Bepridil.Approved
Patent BlueThe therapeutic efficacy of Bepridil can be decreased when used in combination with Patent Blue.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Bepridil.Approved
PazufloxacinThe risk or severity of QTc prolongation can be increased when Pazufloxacin is combined with Bepridil.Investigational
PefloxacinThe risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Bepridil.Approved
PenbutololBepridil may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentaerithritylThe therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Bepridil.Experimental
PentamidineThe risk or severity of QTc prolongation can be increased when Pentamidine is combined with Bepridil.Approved, Investigational
PentazocineThe serum concentration of Pentazocine can be increased when it is combined with Bepridil.Approved, Vet Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Bepridil.Approved, Investigational, Vet Approved
PentoliniumPentolinium may increase the hypotensive activities of Bepridil.Approved
PerflutrenThe risk or severity of QTc prolongation can be increased when Perflutren is combined with Bepridil.Approved
PerindoprilPerindopril may increase the hypotensive activities of Bepridil.Approved
PerindoprilatBepridil may increase the hypotensive activities of Perindoprilat.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Bepridil.Approved
PheniprazinePheniprazine may increase the hypotensive activities of Bepridil.Withdrawn
PheniramineThe risk or severity of QTc prolongation can be increased when Pheniramine is combined with Bepridil.Approved
PhenobarbitalPhenobarbital may increase the hypotensive activities of Bepridil.Approved, Investigational
PhenolphthaleinThe therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Bepridil.Approved, Withdrawn
PhenothiazineThe serum concentration of Phenothiazine can be increased when it is combined with Bepridil.Vet Approved
PhenoxybenzamineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Bepridil.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Bepridil.Withdrawn
PhentolamineThe risk or severity of hypotension can be increased when Phentolamine is combined with Bepridil.Approved
PhenylbutazoneThe therapeutic efficacy of Bepridil can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Bepridil.Approved, Vet Approved
PibrentasvirThe serum concentration of Pibrentasvir can be increased when it is combined with Bepridil.Approved, Investigational
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Bepridil.Approved
PimozideThe risk or severity of QTc prolongation can be increased when Pimozide is combined with Bepridil.Approved
PinacidilPinacidil may increase the hypotensive activities of Bepridil.Approved
PindololBepridil may increase the hypotensive activities of Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Bepridil is combined with Pipamperone.Approved, Investigational
PipecuroniumBepridil may increase the neuromuscular blocking activities of Pipecuronium.Approved
Pipemidic acidThe risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Bepridil.Experimental
PirlindolePirlindole may increase the hypotensive activities of Bepridil.Approved
Piromidic acidThe risk or severity of QTc prolongation can be increased when Piromidic acid is combined with Bepridil.Experimental
PiroxicamThe therapeutic efficacy of Bepridil can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Bepridil can be decreased when used in combination with Pirprofen.Experimental
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Bepridil.Approved
PitolisantThe serum concentration of Bepridil can be decreased when it is combined with Pitolisant.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Bepridil.Withdrawn
PizotifenThe risk or severity of hypotension can be increased when Pizotifen is combined with Bepridil.Approved
Plantago seedThe therapeutic efficacy of Plantago seed can be decreased when used in combination with Bepridil.Approved, Investigational
PlecanatideThe therapeutic efficacy of Plecanatide can be decreased when used in combination with Bepridil.Approved, Investigational
PolycarbophilThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Bepridil.Approved
Polyethylene glycolThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Bepridil.Approved, Vet Approved
PolythiazideBepridil may increase the hypotensive activities of Polythiazide.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Bepridil.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Bepridil.Approved, Investigational
PosaconazoleThe risk or severity of QTc prolongation can be increased when Posaconazole is combined with Bepridil.Approved, Investigational, Vet Approved
Potassium acetateThe therapeutic efficacy of Potassium acetate can be decreased when used in combination with Bepridil.Approved, Investigational
PracinostatThe risk or severity of QTc prolongation can be increased when Pracinostat is combined with Bepridil.Investigational
PractololBepridil may increase the hypotensive activities of Practolol.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Bepridil is combined with Pramipexole.Approved, Investigational
PranoprofenThe therapeutic efficacy of Bepridil can be decreased when used in combination with Pranoprofen.Experimental, Investigational
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Bepridil.Approved
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Bepridil.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Bepridil.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Bepridil.Approved, Vet Approved
PrimaquineThe risk or severity of QTc prolongation can be increased when Primaquine is combined with Bepridil.Approved
PrimidonePrimidone may increase the hypotensive activities of Bepridil.Approved, Vet Approved
ProbucolThe risk or severity of QTc prolongation can be increased when Probucol is combined with Bepridil.Approved, Investigational
ProcainamideThe risk or severity of QTc prolongation can be increased when Procainamide is combined with Bepridil.Approved
ProglumetacinThe therapeutic efficacy of Bepridil can be decreased when used in combination with Proglumetacin.Experimental
PromazineThe risk or severity of QTc prolongation can be increased when Promazine is combined with Bepridil.Approved, Vet Approved
PromethazineThe risk or severity of QTc prolongation can be increased when Promethazine is combined with Bepridil.Approved, Investigational
PropacetamolThe therapeutic efficacy of Bepridil can be decreased when used in combination with Propacetamol.Approved, Investigational
PropafenoneThe risk or severity of QTc prolongation can be increased when Propafenone is combined with Bepridil.Approved
PropericiazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Bepridil.Approved, Investigational
PropiomazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Bepridil.Approved
PropiverineThe risk or severity of hypotension can be increased when Propiverine is combined with Bepridil.Approved, Investigational
PropofolThe risk or severity of QTc prolongation can be increased when Propofol is combined with Bepridil.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Bepridil.Approved, Investigational
PropyphenazoneThe therapeutic efficacy of Bepridil can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Bepridil can be decreased when used in combination with Proquazone.Experimental
ProtriptylineThe risk or severity of QTc prolongation can be increased when Protriptyline is combined with Bepridil.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Bepridil.Approved
PrulifloxacinThe risk or severity of QTc prolongation can be increased when Prulifloxacin is combined with Bepridil.Investigational
QuetiapineThe risk or severity of QTc prolongation can be increased when Quetiapine is combined with Bepridil.Approved
QuinaprilQuinapril may increase the hypotensive activities of Bepridil.Approved, Investigational
QuinaprilatBepridil may increase the hypotensive activities of Quinaprilat.Experimental
QuinidineThe risk or severity of QTc prolongation can be increased when Quinidine is combined with Bepridil.Approved, Investigational
QuinineThe risk or severity of QTc prolongation can be increased when Quinine is combined with Bepridil.Approved
RamiprilRamipril may increase the hypotensive activities of Bepridil.Approved
RamiprilatBepridil may increase the hypotensive activities of Ramiprilat.Experimental
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Bepridil.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Bepridil.Approved, Investigational
RapacuroniumBepridil may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineRasagiline may increase the hypotensive activities of Bepridil.Approved
RavuconazoleThe therapeutic efficacy of Ravuconazole can be increased when used in combination with Bepridil.Investigational
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Bepridil.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Bepridil is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Bepridil.Approved
RescinnamineBepridil may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Bepridil.Approved, Investigational
Rhodamine 6GThe serum concentration of Rhodamine 6G can be increased when it is combined with Bepridil.Experimental
RibociclibThe risk or severity of QTc prolongation can be increased when Bepridil is combined with Ribociclib.Approved, Investigational
RicolinostatThe risk or severity of QTc prolongation can be increased when Ricolinostat is combined with Bepridil.Investigational
RifampicinThe metabolism of Bepridil can be increased when combined with Rifampicin.Approved
RifamycinThe metabolism of Bepridil can be increased when combined with Rifamycin.Investigational
RifapentineThe metabolism of Bepridil can be increased when combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Bepridil.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Bepridil.Approved, Investigational
RilpivirineThe risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Bepridil.Approved
RimexoloneThe metabolism of Bepridil can be increased when combined with Rimexolone.Approved
RiociguatBepridil may increase the hypotensive activities of Riociguat.Approved
RisperidoneBepridil may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe risk or severity of QTc prolongation can be increased when Ritonavir is combined with Bepridil.Approved, Investigational
RituximabBepridil may increase the hypotensive activities of Rituximab.Approved
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Bepridil.Approved
RobenacoxibThe therapeutic efficacy of Bepridil can be decreased when used in combination with Robenacoxib.Experimental, Vet Approved
RocuroniumBepridil may increase the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibThe therapeutic efficacy of Bepridil can be decreased when used in combination with Rofecoxib.Approved, Investigational, Withdrawn
RomidepsinThe risk or severity of QTc prolongation can be increased when Romidepsin is combined with Bepridil.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Bepridil is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Bepridil is combined with Ropivacaine.Approved
RosoxacinThe risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Bepridil.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Bepridil is combined with Rotigotine.Approved
RoxithromycinThe risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Bepridil.Approved, Investigational, Withdrawn
RucaparibThe serum concentration of Rucaparib can be increased when it is combined with Bepridil.Approved, Investigational
RufloxacinThe risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Bepridil.Experimental
RupatadineThe risk or severity of QTc prolongation can be increased when Rupatadine is combined with Bepridil.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Bepridil is combined with Sacubitril.Approved
SafinamideSafinamide may increase the hypotensive activities of Bepridil.Approved, Investigational
SafrazineSafrazine may increase the hypotensive activities of Bepridil.Withdrawn
SalbutamolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Bepridil.Approved, Vet Approved
SalicylamideThe therapeutic efficacy of Bepridil can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Bepridil can be decreased when used in combination with Salicylic acid.Approved, Investigational, Vet Approved
SalmeterolThe risk or severity of QTc prolongation can be increased when Salmeterol is combined with Bepridil.Approved
SalsalateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Salsalate.Approved
SaprisartanBepridil may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirBepridil may increase the arrhythmogenic activities of Saquinavir.Approved, Investigational
SarafloxacinThe risk or severity of QTc prolongation can be increased when Sarafloxacin is combined with Bepridil.Vet Approved, Withdrawn
SarilumabThe therapeutic efficacy of Bepridil can be decreased when used in combination with Sarilumab.Approved, Investigational
SC-236The therapeutic efficacy of Bepridil can be decreased when used in combination with SC-236.Experimental, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Bepridil.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Bepridil.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Bepridil.Approved
SennosidesThe therapeutic efficacy of Sennosides can be decreased when used in combination with Bepridil.Approved
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Bepridil.Approved, Investigational
SertralineThe risk or severity of QTc prolongation can be increased when Sertraline is combined with Bepridil.Approved
SevofluraneThe risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Bepridil.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Bepridil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Bepridil.Approved
SiltuximabThe serum concentration of Bepridil can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Bepridil can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Bepridil.Approved
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Bepridil.Approved, Investigational
SitafloxacinThe risk or severity of QTc prolongation can be increased when Sitafloxacin is combined with Bepridil.Experimental, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Bepridil.Approved, Investigational
SitaxentanBepridil may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Bepridil.Approved
Sodium sulfateThe therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Bepridil.Approved, Vet Approved
Sodium tartrateThe therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Bepridil.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Bepridil.Approved
SolifenacinThe risk or severity of QTc prolongation can be increased when Solifenacin is combined with Bepridil.Approved
SomatostatinThe serum concentration of Somatostatin can be increased when it is combined with Bepridil.Approved, Investigational
SorafenibThe risk or severity of QTc prolongation can be increased when Sorafenib is combined with Bepridil.Approved, Investigational
SorbitolThe therapeutic efficacy of Sorbitol can be decreased when used in combination with Bepridil.Approved
SotalolThe risk or severity of QTc prolongation can be increased when Sotalol is combined with Bepridil.Approved
SparfloxacinThe risk or severity of QTc prolongation can be increased when Bepridil is combined with Sparfloxacin.Approved, Investigational
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Bepridil.Experimental
SpiraprilBepridil may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Bepridil is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Bepridil can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanoloneThe serum concentration of Stanolone can be increased when it is combined with Bepridil.Illicit, Investigational
Stanolone acetateThe serum concentration of Stanolone acetate can be increased when it is combined with Bepridil.Experimental
StiripentolThe serum concentration of Bepridil can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Bepridil is combined with Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Bepridil is combined with Sufentanil.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Bepridil.Approved
SulfamethoxazoleThe risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Bepridil.Approved
SulfasalazineThe therapeutic efficacy of Bepridil can be decreased when used in combination with Sulfasalazine.Approved
SulfisoxazoleThe risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Bepridil.Approved, Vet Approved
SulindacThe therapeutic efficacy of Bepridil can be decreased when used in combination with Sulindac.Approved, Investigational
SulpirideThe risk or severity of QTc prolongation can be increased when Sulpiride is combined with Bepridil.Approved, Investigational
SultoprideThe risk or severity of QTc prolongation can be increased when Sultopride is combined with Bepridil.Experimental
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Bepridil.Approved, Investigational
SunitinibThe risk or severity of QTc prolongation can be increased when Sunitinib is combined with Bepridil.Approved, Investigational
SuprofenThe therapeutic efficacy of Bepridil can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Bepridil can be decreased when used in combination with Suxibuzone.Experimental
TacrineThe serum concentration of Tacrine can be increased when it is combined with Bepridil.Investigational, Withdrawn
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Bepridil.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Bepridil.Approved, Investigational
TalinololThe serum concentration of Talinolol can be increased when it is combined with Bepridil.Investigational
TalniflumateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Talniflumate.Approved
TamoxifenThe risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Bepridil.Approved
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Bepridil.Approved, Investigational
TandutinibThe risk or severity of QTc prolongation can be increased when Tandutinib is combined with Bepridil.Investigational
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Bepridil.Experimental
Technetium Tc-99m ciprofloxacinThe risk or severity of QTc prolongation can be increased when Technetium Tc-99m ciprofloxacin is combined with Bepridil.Investigational
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Bepridil.Approved, Investigational
TegaserodThe therapeutic efficacy of Tegaserod can be decreased when used in combination with Bepridil.Approved, Investigational, Withdrawn
TelaprevirThe serum concentration of Bepridil can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelavancinThe risk or severity of QTc prolongation can be increased when Telavancin is combined with Bepridil.Approved
TelithromycinThe risk or severity of QTc prolongation can be increased when Telithromycin is combined with Bepridil.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Bepridil.Approved, Investigational
TemafloxacinThe risk or severity of QTc prolongation can be increased when Temafloxacin is combined with Bepridil.Withdrawn
TemocaprilBepridil may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Bepridil.Approved
TenidapThe therapeutic efficacy of Bepridil can be decreased when used in combination with Tenidap.Experimental
TeniposideThe serum concentration of Teniposide can be increased when it is combined with Bepridil.Approved
TenoxicamThe therapeutic efficacy of Bepridil can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Bepridil can be decreased when used in combination with Tepoxalin.Vet Approved
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Bepridil.Approved
TerbutalineThe risk or severity of QTc prolongation can be increased when Terbutaline is combined with Bepridil.Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Bepridil.Approved
TerfenadineThe risk or severity of QTc prolongation can be increased when Bepridil is combined with Terfenadine.Approved, Withdrawn
TerlipressinThe risk or severity of QTc prolongation can be increased when Terlipressin is combined with Bepridil.Approved, Investigational
TerodilineThe risk or severity of QTc prolongation can be increased when Bepridil is combined with Terodiline.Experimental
Testosterone propionateThe serum concentration of Testosterone propionate can be increased when it is combined with Bepridil.Approved, Investigational, Vet Approved, Withdrawn
TetrabenazineThe risk or severity of QTc prolongation can be increased when Tetrabenazine is combined with Bepridil.Approved, Investigational
TetracyclineThe serum concentration of Tetracycline can be increased when it is combined with Bepridil.Approved, Vet Approved
TetrahydropalmatineBepridil may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Bepridil is combined with Thalidomide.Approved, Investigational, Withdrawn
TheophyllineTheophylline may increase the antihypertensive activities of Bepridil.Approved
ThiamylalThiamylal may increase the hypotensive activities of Bepridil.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Bepridil.Approved, Vet Approved
ThioproperazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Bepridil.Approved
ThioridazineThe risk or severity of QTc prolongation can be increased when Thioridazine is combined with Bepridil.Approved, Withdrawn
ThiothixeneThe risk or severity of QTc prolongation can be increased when Thiothixene is combined with Bepridil.Approved
Tiaprofenic acidThe therapeutic efficacy of Bepridil can be decreased when used in combination with Tiaprofenic acid.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Bepridil.Approved
TicrynafenBepridil may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe serum concentration of Timolol can be increased when it is combined with Bepridil.Approved
TinoridineThe therapeutic efficacy of Bepridil can be decreased when used in combination with Tinoridine.Investigational
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Bepridil.Approved
TipranavirThe risk or severity of QTc prolongation, torsade de pointes, and Cardiac Arrhythmia can be increased when Tipranavir is combined with Bepridil.Approved, Investigational
TizanidineThe risk or severity of QTc prolongation can be increased when Tizanidine is combined with Bepridil.Approved, Investigational
TocilizumabThe serum concentration of Bepridil can be decreased when it is combined with Tocilizumab.Approved
TocopherylquinoneBepridil may increase the hypotensive activities of Tocopherylquinone.Experimental, Investigational
TolazolineThe risk or severity of hypotension can be increased when Tolazoline is combined with Bepridil.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Bepridil is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe therapeutic efficacy of Bepridil can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
TolmetinThe therapeutic efficacy of Bepridil can be decreased when used in combination with Tolmetin.Approved
TolonidineBepridil may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Bepridil.Approved
TolterodineThe risk or severity of QTc prolongation can be increased when Tolterodine is combined with Bepridil.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Bepridil.Approved
TopiramateThe serum concentration of Topiramate can be increased when it is combined with Bepridil.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Bepridil.Approved, Investigational
TorasemideTorasemide may increase the hypotensive activities of Bepridil.Approved
ToremifeneThe risk or severity of QTc prolongation can be increased when Toremifene is combined with Bepridil.Approved, Investigational
TrandolaprilTrandolapril may increase the hypotensive activities of Bepridil.Approved
TranylcypromineTranylcypromine may increase the hypotensive activities of Bepridil.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Bepridil.Approved, Investigational
TravoprostTravoprost may increase the hypotensive activities of Bepridil.Approved
TrazodoneThe risk or severity of QTc prolongation can be increased when Trazodone is combined with Bepridil.Approved, Investigational
TreprostinilThe risk or severity of QTc prolongation can be increased when Treprostinil is combined with Bepridil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Bepridil is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Bepridil is combined with Triamterene.Approved
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Bepridil.Approved, Vet Approved
TrifluoperazineThe risk or severity of hypotension can be increased when Trifluoperazine is combined with Bepridil.Approved, Investigational
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Bepridil.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Bepridil.Approved, Investigational
TrimethoprimThe risk or severity of QTc prolongation can be increased when Trimethoprim is combined with Bepridil.Approved, Vet Approved
TrimipramineThe risk or severity of QTc prolongation can be increased when Trimipramine is combined with Bepridil.Approved
TriprolidineThe risk or severity of QTc prolongation can be increased when Triprolidine is combined with Bepridil.Approved
TriptorelinThe risk or severity of QTc prolongation can be increased when Triptorelin is combined with Bepridil.Approved, Vet Approved
Trolamine salicylateThe therapeutic efficacy of Bepridil can be decreased when used in combination with Trolamine salicylate.Approved
TroleandomycinThe metabolism of Bepridil can be decreased when combined with Troleandomycin.Approved
TrovafloxacinThe risk or severity of QTc prolongation can be increased when Trovafloxacin is combined with Bepridil.Approved, Investigational, Withdrawn
TubocurarineBepridil may increase the neuromuscular blocking activities of Tubocurarine.Approved
TucidinostatThe risk or severity of QTc prolongation can be increased when Tucidinostat is combined with Bepridil.Investigational
UbidecarenoneThe serum concentration of Ubidecarenone can be increased when it is combined with Bepridil.Approved, Investigational, Nutraceutical
UdenafilUdenafil may increase the antihypertensive activities of Bepridil.Approved, Investigational
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Bepridil.Approved
UnoprostoneBepridil may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Bepridil.Investigational
ValdecoxibThe therapeutic efficacy of Bepridil can be decreased when used in combination with Valdecoxib.Approved, Investigational, Withdrawn
ValinomycinThe serum concentration of Valinomycin can be increased when it is combined with Bepridil.Experimental
Valproic AcidThe risk or severity of QTc prolongation can be increased when Valproic Acid is combined with Bepridil.Approved, Investigational
ValsartanValsartan may increase the hypotensive activities of Bepridil.Approved, Investigational
ValspodarThe serum concentration of Valspodar can be increased when it is combined with Bepridil.Investigational
VandetanibThe risk or severity of QTc prolongation can be increased when Vandetanib is combined with Bepridil.Approved
VardenafilThe risk or severity of QTc prolongation can be increased when Vardenafil is combined with Bepridil.Approved
VecuroniumBepridil may increase the neuromuscular blocking activities of Vecuronium.Approved
VelpatasvirThe serum concentration of Velpatasvir can be increased when it is combined with Bepridil.Approved, Investigational
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Bepridil.Approved, Investigational
VenlafaxineThe risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Bepridil.Approved
VerapamilThe risk or severity of hypotension can be increased when Verapamil is combined with Bepridil.Approved
VilanterolThe risk or severity of QTc prolongation can be increased when Vilanterol is combined with Bepridil.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Bepridil.Approved
VincamineBepridil may increase the hypotensive activities of Vincamine.Experimental
VincristineThe excretion of Vincristine can be decreased when combined with Bepridil.Approved, Investigational
VinflunineThe serum concentration of Vinflunine can be increased when it is combined with Bepridil.Approved, Investigational
VinorelbineThe serum concentration of Vinorelbine can be increased when it is combined with Bepridil.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Bepridil.Approved, Investigational
VoriconazoleThe risk or severity of QTc prolongation can be increased when Voriconazole is combined with Bepridil.Approved, Investigational
VorinostatThe risk or severity of QTc prolongation can be increased when Vorinostat is combined with Bepridil.Approved, Investigational
VoxilaprevirThe serum concentration of Voxilaprevir can be increased when it is combined with Bepridil.Approved, Investigational
XipamideBepridil may increase the hypotensive activities of Xipamide.Experimental
YohimbineYohimbine may decrease the antihypertensive activities of Bepridil.Approved, Investigational, Vet Approved
ZaltoprofenThe therapeutic efficacy of Bepridil can be decreased when used in combination with Zaltoprofen.Approved, Investigational
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Bepridil.Approved
ZiprasidoneThe risk or severity of QTc prolongation can be increased when Ziprasidone is combined with Bepridil.Approved
ZofenoprilBepridil may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe therapeutic efficacy of Bepridil can be decreased when used in combination with Zomepirac.Withdrawn
ZuclopenthixolThe risk or severity of QTc prolongation can be increased when Zuclopenthixol is combined with Bepridil.Approved, Investigational
Food Interactions
  • Alcohol may further decrease blood pressure and increase dizziness and drowsiness
  • Take with food to reduce nausea.

References

Synthesis Reference

Mauvernay, R.Y., Busch, N., Moleyre, J., Monteil, A. and Simond, J.; U.S. Patent 3,962,238; June 8,1976; assigned to Centre Europeen de Recherches Mauvernay "CERM".

General References
Not Available
External Links
Human Metabolome Database
HMDB0015374
KEGG Compound
C06847
PubChem Compound
2351
PubChem Substance
46506353
ChemSpider
2261
BindingDB
78577
ChEBI
3061
ChEMBL
CHEMBL1008
Therapeutic Targets Database
DAP000525
PharmGKB
PA164754755
IUPHAR
2337
Guide to Pharmacology
GtP Drug Page
HET
BEP
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Bepridil
ATC Codes
C08EA02 — Bepridil

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)128Mauvernay, R.Y., Busch, N., Moleyre, J., Monteil, A. and Simond, J.; U.S. Patent 3,962,238; June 8,1976; assigned to Centre Europeen de Recherches Mauvernay "CERM".
water solubilitySlightly solubleNot Available
logP5.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00655 mg/mLALOGPS
logP5.33ALOGPS
logP5.49ChemAxon
logS-4.8ALOGPS
pKa (Strongest Basic)9.16ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area15.71 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity115.12 m3·mol-1ChemAxon
Polarizability43.5 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9859
Blood Brain Barrier+0.9003
Caco-2 permeable+0.5593
P-glycoprotein substrateSubstrate0.7013
P-glycoprotein inhibitor IInhibitor0.7951
P-glycoprotein inhibitor IIInhibitor0.8387
Renal organic cation transporterInhibitor0.6774
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateSubstrate0.5495
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorNon-inhibitor0.8462
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5636
Ames testNon AMES toxic0.67
CarcinogenicityNon-carcinogens0.8688
BiodegradationNot ready biodegradable0.9938
Rat acute toxicity2.4903 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.536
hERG inhibition (predictor II)Inhibitor0.796
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylbenzamines. These are aromatic compounds consisting of a benzyl group that is N-linked to a benzamine.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylmethylamines
Direct Parent
Phenylbenzamines
Alternative Parents
Dialkylarylamines / Benzylamines / Aniline and substituted anilines / Aralkylamines / N-alkylpyrrolidines / Trialkylamines / Dialkyl ethers / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Phenylbenzamine / Benzylamine / Tertiary aliphatic/aromatic amine / Aniline or substituted anilines / Dialkylarylamine / Aralkylamine / N-alkylpyrrolidine / Pyrrolidine / Tertiary amine / Tertiary aliphatic amine
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
tertiary amine, pyrrolidines (CHEBI:3061)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1A
Uniprot ID
O00555
Uniprot Name
Voltage-dependent P/Q-type calcium channel subunit alpha-1A
Molecular Weight
282362.39 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Bezprozvanny I, Tsien RW: Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967). Mol Pharmacol. 1995 Sep;48(3):540-9. [PubMed:7565636]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Scaffold protein binding
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1H
Uniprot ID
O95180
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1H
Molecular Weight
259160.2 Da
References
  1. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221]
  2. Bezprozvanny I, Tsien RW: Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967). Mol Pharmacol. 1995 Sep;48(3):540-9. [PubMed:7565636]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated calcium channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Acts as a regulatory subunit for P/Q-t...
Gene Name
CACNA2D2
Uniprot ID
Q9NY47
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-2
Molecular Weight
129816.095 Da
References
  1. Cohen CJ, Spires S, Van Skiver D: Block of T-type Ca channels in guinea pig atrial cells by antiarrhythmic agents and Ca channel antagonists. J Gen Physiol. 1992 Oct;100(4):703-28. [PubMed:1281221]
  2. Bezprozvanny I, Tsien RW: Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967). Mol Pharmacol. 1995 Sep;48(3):540-9. [PubMed:7565636]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hormone binding
Specific Function
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates th...
Gene Name
ATP1A1
Uniprot ID
P05023
Uniprot Name
Sodium/potassium-transporting ATPase subunit alpha-1
Molecular Weight
112895.01 Da
References
  1. Kovacic H, Gallice P, Crevat A: Inhibition of sodium pump by bepridil. An in vitro and microcalorimetric study. Biochem Pharmacol. 1992 Oct 20;44(8):1529-34. [PubMed:1329768]
  2. Raess BU, Record DM: Inhibition of erythrocyte Ca2(+)-pump by Ca2+ antagonists. Biochem Pharmacol. 1990 Dec 1;40(11):2549-55. [PubMed:2148481]
  3. Smith SJ, England PJ: The effects of reported Ca2+ sensitisers on the rates of Ca2+ release from cardiac troponin C and the troponin-tropomyosin complex. Br J Pharmacol. 1990 Aug;100(4):779-85. [PubMed:2207500]
  4. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041]
  5. Fuchs J, Mainka L, Reifart N, Zimmer G: Effects of bepridil on heart mitochondrial membrane and the isolated rat heart preparation. Arzneimittelforschung. 1986 Feb;36(2):209-12. [PubMed:2938592]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Potassium channel that plays an important role in a number of tissues, including heart, inner ear, stomach and colon (By similarity) (PubMed:10646604). Associates with KCNE beta subunits that modul...
Gene Name
KCNQ1
Uniprot ID
P51787
Uniprot Name
Potassium voltage-gated channel subfamily KQT member 1
Molecular Weight
74697.925 Da
References
  1. Chouabe C, Drici MD, Romey G, Barhanin J: Effects of calcium channel blockers on cloned cardiac K+ channels IKr and IKs. Therapie. 2000 Jan-Feb;55(1):195-202. [PubMed:10860024]
  2. Yumoto Y, Horie M, Kubota T, Ninomiya T, Kobori A, Takenaka K, Takano M, Niwano S, Izumi T: Bepridil block of recombinant human cardiac IKs current shows a time-dependent unblock. J Cardiovasc Pharmacol. 2004 Feb;43(2):178-82. [PubMed:14716203]
  3. Chouabe C, Drici MD, Romey G, Barhanin J, Lazdunski M: HERG and KvLQT1/IsK, the cardiac K+ channels involved in long QT syndromes, are targets for calcium channel blockers. Mol Pharmacol. 1998 Oct;54(4):695-703. [PubMed:9765513]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other
General Function
Troponin t binding
Specific Function
Troponin is the central regulatory protein of striated muscle contraction. Tn consists of three components: Tn-I which is the inhibitor of actomyosin ATPase, Tn-T which contains the binding site fo...
Gene Name
TNNC1
Uniprot ID
P63316
Uniprot Name
Troponin C, slow skeletal and cardiac muscles
Molecular Weight
18402.36 Da
References
  1. Abusamhadneh E, Abbott MB, Dvoretsky A, Finley N, Sasi S, Rosevear PR: Interaction of bepridil with the cardiac troponin C/troponin I complex. FEBS Lett. 2001 Sep 28;506(1):51-4. [PubMed:11591369]
  2. Wang X, Li MX, Sykes BD: Structure of the regulatory N-domain of human cardiac troponin C in complex with human cardiac troponin I147-163 and bepridil. J Biol Chem. 2002 Aug 23;277(34):31124-33. Epub 2002 Jun 11. [PubMed:12060657]
  3. MacLachlan LK, Reid DG, Mitchell RC, Salter CJ, Smith SJ: Binding of a calcium sensitizer, bepridil, to cardiac troponin C. A fluorescence stopped-flow kinetic, circular dichroism, and proton nuclear magnetic resonance study. J Biol Chem. 1990 Jun 15;265(17):9764-70. [PubMed:2351672]
  4. Kleerekoper Q, Liu W, Choi D, Putkey JA: Identification of binding sites for bepridil and trifluoperazine on cardiac troponin C. J Biol Chem. 1998 Apr 3;273(14):8153-60. [PubMed:9525919]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Titin binding
Specific Function
Calmodulin mediates the control of a large number of enzymes, ion channels, aquaporins and other proteins by Ca(2+). Among the enzymes to be stimulated by the calmodulin-Ca(2+) complex are a number...
Gene Name
CALM1
Uniprot ID
P0DP23
Uniprot Name
Calmodulin
Molecular Weight
16837.47 Da
References
  1. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041]
  2. Lamers JM, Verdouw PD, Mas-Oliva J: The effects of felodipine and bepridil on calcium-stimulated calmodulin binding and calcium pumping ATPase of cardiac sarcolemma before and after removal of endogenous calmodulin. Mol Cell Biochem. 1987 Dec;78(2):169-76. [PubMed:2964559]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a preference for cGMP as...
Gene Name
PDE1B
Uniprot ID
Q01064
Uniprot Name
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B
Molecular Weight
61379.235 Da
References
  1. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes. Has a higher affinity for cG...
Gene Name
PDE1A
Uniprot ID
P54750
Uniprot Name
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A
Molecular Weight
61251.38 Da
References
  1. Lamers JM, Cysouw KJ, Verdouw PD: Slow calcium channel blockers and calmodulin. Effect of felodipine, nifedipine, prenylamine and bepridil on cardiac sarcolemmal calcium pumping ATPase. Biochem Pharmacol. 1985 Nov 1;34(21):3837-43. [PubMed:2933041]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
Molecular Weight
126653.52 Da
References
  1. Chiu PJ, Marcoe KF, Bounds SE, Lin CH, Feng JJ, Lin A, Cheng FC, Crumb WJ, Mitchell R: Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels. J Pharmacol Sci. 2004 Jul;95(3):311-9. [PubMed:15272206]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Uesawa Y, Takeuchi T, Mohri K: Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17. [PubMed:22039822]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Ibrahim S, Peggins J, Knapton A, Licht T, Aszalos A: Influence of antipsychotic, antiemetic, and Ca(2+) channel blocker drugs on the cellular accumulation of the anticancer drug daunorubicin: P-glycoprotein modulation. J Pharmacol Exp Ther. 2000 Dec;295(3):1276-83. [PubMed:11082465]

Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 07:53